Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD

Blood (2019) 134 (Supplement_1): 626.

https://doi.org/10.1182/blood-2019-123689

Published: 2019

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Maria Gavriatopoulou, MD, Evangelos Terpos, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Evangelos Eleutherakis-Papaiakovou, MD, Athanasios Papatheodorou, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, MD, Ioanna Dialoupi, MD, Maria Roussou, MD, Nikoletta-Aikaterini Kokkali, Eftathios Kastritis, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3118.

https://doi.org/10.1182/blood-2019-123916

Published: 2019

Journal Articles

Acute Myeloid Leukemia Expands Osteoprogenitor Rich Niche in the Bone Marrow but Resorbs Mature Bone Causing Osteopenia/Osteoporosis in Animal Models

Bin Yuan, Stanley Ly, Khoa Nguyen, Vivien Tran, Kiersten Maldonado, Charles Kinglsey, Jared K Burks, PhD, Xin Zhou, PhD, Benoit deCrombrugghe, Michael Andreeff, MD PhD, Venkata Lokesh Battula, PhD

Blood (2018) 132 (Supplement 1): 86.

https://doi.org/10.1182/blood-2018-99-117258

Published: 2018

Journal Articles

The Exosomes-Derived EGFR Ligand Amphiregulin (AREG) Is a New Pro-Osteoclastogenic Factor in Multiple Myeloma

Emanuela Vicario, PhD, Stefania Raimondo, PhD, Laura Saieva, PhD, Federica Costa, PhD, Vincenza Tinnirello, Fabrizio Accardi, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD, Riccardo Alessandro, PhD

Blood (2017) 130 (Supplement 1): 1776.

https://doi.org/10.1182/blood.V130.Suppl_1.1776.1776

Published: 2017

Journal Articles

Depletion of Mature B Cells By Anti CD20-Directed Antibody Induces Trabecular Bone Loss in Young Mice: An Alert for Clinicians?

Albert Kolomansky, MD, Naamit Deshet-Unger, PhD, Alina Ostrovsky, Nathalie Ben-Califa, PhD, Sahar Hiram-Bab, PhD, Tamar Liron, PhD, Howard S. Oster, MD PhD, Moshe Mittelman, MD, Yankel Gabet, DMD, PhD, Drorit Neumann, PhD

Blood (2017) 130 (Supplement 1): 5642.

https://doi.org/10.1182/blood.V130.Suppl_1.5642.5642

Published: 2017

Journal Articles

RANK-RANKL Mediated Bone Destruction in B-Cell Acute Lymphoblastic Leukemia

Sujeetha A. Rajakumar, MSc, Eniko Papp, PhD, Ildiko Grandal, MSc, Daniele Merico, PhD, Careesa C. Liu, MSc, Bedilu Allo, PhD, Lucia Zhang, Marc Grynpas, PhD, Mark D. Minden, MD PhD, Johann K. Hitzler, MD, Cynthia J. Guidos, PhD, Jayne S. Danska, PhD

Blood (2016) 128 (22): 908.

https://doi.org/10.1182/blood.V128.22.908.908

Published: 2016

Journal Articles

Strong Immunoexpression of Dickkopf-1 Is Associated with Response to Bortezomib in Multiple Myeloma

Yong Won Choi, MD, Tae Hwan Kim, MD, Seong Hyun Jeong, MD, Jae Ho Han, MD, Joon Seong Park

Blood (2016) 128 (22): 3270.

https://doi.org/10.1182/blood.V128.22.3270.3270

Published: 2016

Journal Articles

Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression

Benedetta Dalla Palma, MD, Valentina Marchica, Fabrizio Accardi, MD, Daniela Guasco, Laura Notarfranchi, MD, Federica Costa, Martina Caviola, Federica De Luca, Luisa Craviotto, MD, Mario Pedrazzoni, MD PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2016) 128 (22): 4452.

https://doi.org/10.1182/blood.V128.22.4452.4452

Published: 2016

Journal Articles

Myeloma Cells Induce High Level of TAF12 Expression in Bone Marrow Stromal Cells, Resulting in Increased Osteoclastogenesis and Myeloma Cell Growth in Response to 1,25(OH) 2 D 3

Yasuhisa Ohata, MD PhD, John M Chirgwin, PhD, Jolene J Windle, PhD, G. David Roodman, MD PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2016) 128 (22): 4421.

https://doi.org/10.1182/blood.V128.22.4421.4421

Published: 2016

Journal Articles

Prognostic Value of the Parameters of Myeloma Bone Disease Signaling in Patients with Newly Diagnosed Multiple Myeloma Treated with Proteasome Inhibitors

Jiri Minarik, MD PhD, Zuzana Hermanova, Jan Hrbek, Pavla Petrova, Patrik Flodr, Petra Krhovska, Tomas Pika, Jaroslav Bacovsky, Miroslav Herman, Vlastimil Scudla

Blood (2016) 128 (22): 5603.

https://doi.org/10.1182/blood.V128.22.5603.5603

Published: 2016

Journal Articles

Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group

Evangelos Terpos, Eirini Katodritou, Argiris Symeonidis, Flora Zagouri, Antonis Gerofotis, Georgia Christopoulou, Maria Gavriatopoulou, Dimitrios Christoulas, Alexandra Kourakli, Pavlina Konstantinidou, Efstathios Kastritis, MD, Meletios A Dimopoulos

Blood (2016) 128 (22): 4488.

https://doi.org/10.1182/blood.V128.22.4488.4488

Published: 2016

Journal Articles

Novel In Vivo Model of Multiple Myeloma Bone Disease Using ß-Tricalcium Phosphate Artificial Bone Grafts

Miroslav Koulnis, PhD, Homare Eda, MDPhD, Loredana Santo, MD, Ka Tat Siu, PhD, Janani Ramachandran, MA, Cristina Panaroni, PhD, Takaaki Tanaka, MD PhD, Noopur S. Raje, MD

Blood (2015) 126 (23): 4200.

https://doi.org/10.1182/blood.V126.23.4200.4200

Published: 2015

Journal Articles

Assessment of the Parameters of Myeloma Bone Disease Signaling to the Extent of Skeletal Involvement, Bone Mineral Turnover and Activity of Multiple Myeloma

Jiri Minarik, Zuzana Hermanova, Pavla Petrova, Jana Zapletalova, Jan Hrbek, Petra Pusciznova, Jaroslav Bacovsky, Tomas Pika, Miroslav Herman, Vlastimil Scudla

Blood (2015) 126 (23): 1754.

https://doi.org/10.1182/blood.V126.23.1754.1754

Published: 2015

Journal Articles

Disulfiram Combined with Copper Induces Acute Myeloid Leukemic Stem-like KG1a Cell Apoptosis through TNF-a/ROS Pathway

Bing Xu, PhD, Yong Zhou, Manman Deng, Wenbin Zhong, Kai Chen, Huijuan Dong, Daoguang Yan, Shuyun Zhou

Blood (2015) 126 (23): 4923.

https://doi.org/10.1182/blood.V126.23.4923.4923

Published: 2015

Journal Articles

The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia

Panagiotis Anagnostis, Sofia Vakalopoulou, Dimitrios Christoulas, Spyridon Karras, Athanasios Papatheodorou, Eirini Katodritou, Panagiotis Kokkoris, Vasilia Garipidou, Evangelos Terpos

Blood (2015) 126 (23): 2284.

https://doi.org/10.1182/blood.V126.23.2284.2284

Published: 2015

Journal Articles

Differential Activity of Brain Derived Neurotrophic Factor (BDNF) and RANKL in Promoting Osteoclast Activity in Multiple Myeloma Patients with or without Bone Disease

Bhagavathi A Narayanan, PhD, Cronstein Bruce, MD, Mediero Aranzazu,, PhD, Amitabha Mazumder, MD

Blood (2014) 124 (21): 2058.

https://doi.org/10.1182/blood.V124.21.2058.2058

Published: 2014

Journal Articles

Age-Associated Bone Disease in Factor VIII-Deficient Mice

Emily A. Larson, Urszula T. Iwaniec, PhD, Sigrid C. Holmgren, MS, Russell T. Turner, PhD, Michael Recht, MD PhD, Jason A. Taylor, MD PhD

Blood (2014) 124 (21): 2798.

https://doi.org/10.1182/blood.V124.21.2798.2798

Published: 2014

Journal Articles

The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Evangelos Terpos, Efstathios Kastritis, MD, Dimitrios Christoulas, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Despoina Kalapanida, Marios Bakogeorgos, Maria Roussou, Meletios A. Dimopoulos

Blood (2014) 124 (21): 3462.

https://doi.org/10.1182/blood.V124.21.3462.3462

Published: 2014

NARROW

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Acute Myeloid Leukemia Expands Osteoprogenitor Rich Niche in the Bone Marrow but Resorbs Mature Bone Causing Osteopenia/Osteoporosis in Animal Models

The Exosomes-Derived EGFR Ligand Amphiregulin (AREG) Is a New Pro-Osteoclastogenic Factor in Multiple Myeloma

Depletion of Mature B Cells By Anti CD20-Directed Antibody Induces Trabecular Bone Loss in Young Mice: An Alert for Clinicians?

RANK-RANKL Mediated Bone Destruction in B-Cell Acute Lymphoblastic Leukemia

Strong Immunoexpression of Dickkopf-1 Is Associated with Response to Bortezomib in Multiple Myeloma

Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression

Myeloma Cells Induce High Level of TAF12 Expression in Bone Marrow Stromal Cells, Resulting in Increased Osteoclastogenesis and Myeloma Cell Growth in Response to 1,25(OH) 2 D 3

Prognostic Value of the Parameters of Myeloma Bone Disease Signaling in Patients with Newly Diagnosed Multiple Myeloma Treated with Proteasome Inhibitors

Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group

Novel In Vivo Model of Multiple Myeloma Bone Disease Using ß-Tricalcium Phosphate Artificial Bone Grafts

Assessment of the Parameters of Myeloma Bone Disease Signaling to the Extent of Skeletal Involvement, Bone Mineral Turnover and Activity of Multiple Myeloma

Disulfiram Combined with Copper Induces Acute Myeloid Leukemic Stem-like KG1a Cell Apoptosis through TNF-a/ROS Pathway

The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia

Differential Activity of Brain Derived Neurotrophic Factor (BDNF) and RANKL in Promoting Osteoclast Activity in Multiple Myeloma Patients with or without Bone Disease

Age-Associated Bone Disease in Factor VIII-Deficient Mice

The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only